Abstract
The development of novel treatment strategies for therapy of angiogenesis-dependent diseases requires identification of specific tumor endothelial cell markers to which therapeutic agents can be targeted. This can be achieved by random or targeted approaches. Random approaches are based on genomic screening to identify differences between normal and activated endothelium. Targeted approaches utilize known angiogenesis inhibitors to find their molecular targets. Both approaches may lead to the development of angiostatic therapies that are directly targeted towards activated endothelial cells. This review summarizes the recent developments in both approaches.
Keywords: HUVEC proliferation, angiogenesis, NGR binding motifs, endothelial cell based targets, Tumor
Current Pharmaceutical Design
Title: Identification of Novel Drug Targets for Angiostatic Cancer Therapy; It Takes Two to Tango
Volume: 13 Issue: 35
Author(s): Victor L.J.L. Thijssen, Judy R. van Beijnum, Kevin H. Mayo and Arjan W. Griffioen
Affiliation:
Keywords: HUVEC proliferation, angiogenesis, NGR binding motifs, endothelial cell based targets, Tumor
Abstract: The development of novel treatment strategies for therapy of angiogenesis-dependent diseases requires identification of specific tumor endothelial cell markers to which therapeutic agents can be targeted. This can be achieved by random or targeted approaches. Random approaches are based on genomic screening to identify differences between normal and activated endothelium. Targeted approaches utilize known angiogenesis inhibitors to find their molecular targets. Both approaches may lead to the development of angiostatic therapies that are directly targeted towards activated endothelial cells. This review summarizes the recent developments in both approaches.
Export Options
About this article
Cite this article as:
Thijssen L.J.L. Victor, van Beijnum R. Judy, Mayo H. Kevin and Griffioen W. Arjan, Identification of Novel Drug Targets for Angiostatic Cancer Therapy; It Takes Two to Tango, Current Pharmaceutical Design 2007; 13 (35) . https://dx.doi.org/10.2174/138161207782794121
DOI https://dx.doi.org/10.2174/138161207782794121 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New and Highly Potent Antitumor Natural Products from Marine-Derived Fungi: Covering the Period from 2003 to 2012
Current Topics in Medicinal Chemistry Recent Patents Review on Intranasal Administration for CNS Drug Delivery
Recent Patents on Drug Delivery & Formulation Epigenetic Regulation of Epithelial-Mesenchymal Transition by Hypoxia in Cancer: Targets and Therapy
Current Pharmaceutical Design Mitochondrial Superoxide Dismutase - Signals of Distinction
Anti-Cancer Agents in Medicinal Chemistry Mechanisms of Tumor Cell Necrosis
Current Pharmaceutical Design Smart Electrospun Nanofibers for Controlled Drug Release: Recent Advances and New Perspectives
Current Pharmaceutical Design New Alkyl-Lipid Blockers of SK3 Channels Reduce Cancer Cell Migration and Occurrence of Metastasis
Current Cancer Drug Targets Advancing Drug Therapy for Brain Tumours: A Current Review of the Pro-inflammatory Peptide Substance P and its Antagonists as Anti-cancer Agents
Recent Patents on CNS Drug Discovery (Discontinued) Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells
Current Medicinal Chemistry Cell Cycle and Cancer: The G1 Restriction Point and the G1 / S Transition
Current Genomics Synthesis and Biological Activities of Organotin(IV) Complexes as Antitumoral and Antimicrobial Agents. A Review
Mini-Reviews in Medicinal Chemistry Preventive and Protective Roles of Dietary Nrf2 Activators Against Central Nervous System Diseases
CNS & Neurological Disorders - Drug Targets Natural Compounds as Anticancer Agents Targeting DNA Topoisomerases
Current Genomics Brain Delivery Systems via Mechanism Independent of Receptor-Mediated Endocytosis and Adsorptive-Mediated Endocytosis
Current Pharmaceutical Biotechnology Specific Targeting of Akt Kinase Isoforms: Taking the Precise Path for Prevention and Treatment of Cancer
Current Drug Targets Recent Advances and Approaches in Targeting Apoptosis Signaling Pathways for Anti-Cancer Therapeutics
Current Cancer Therapy Reviews G Protein-Coupled Receptor Fusion Proteins in Drug Discovery
Current Pharmaceutical Design Brain Tumor Causes, Symptoms, Diagnosis and Radiotherapy Treatment
Current Medical Imaging Recent Advances in Design of Potential Quinoxaline Anti-Infectives
Current Medicinal Chemistry Searching for Novel Cancer Chemopreventive Plants and their Products:The Genus Zanthoxylum
Current Drug Targets